 |
|
|
| |
Healthy Volunteer First-in-Human Evaluation of GS-5816, a Novel Second Generation Broad-Genotypic NS5A Inhibitor With Potential for Once-Daily Dosing
|
| |
| |
Reported by Jules Levin
EASL 2013 April 28 Amsterdam
Polina German, Anita A. Mathias, Philip S. Pang, Chris Yang, Lingling Han, John O. Link, John McNally, Brian P. Kearney
Gilead Sciences, Inc., Foster City, CA, USA
|
| |
|
|
|
|
|
